http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Personalis receives Medicare coverage for cancer test monitoring
-
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
-
Personalis Reports First Quarter Results and Recent Highlights
-
Personalis to Announce First Quarter 2026 Financial Results
-
Personalis presents clinical data on cancer monitoring technology at AACR
-
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
-
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
-
Personalis to Participate in the 25th Annual Needham Virtual Conference
-
Personalis promotes Dr. Richard Chen to president role
-
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
-
Personalis publishes breast cancer study in Journal of Clinical Oncology
-
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
-
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
-
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
-
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
-
Personalis gains Medicare coverage for lung cancer test
-
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
-
Personalis study shows ctDNA test detects immunotherapy response early
-
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
-
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
-
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
-
Personalis study shows blood test predicts cancer patient outcomes
-
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
-
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
-
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
-
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
-
Personalis Reports Third Quarter 2025 Financial Results
-
Personalis to Announce Third Quarter 2025 Financial Results
-
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
-
Personalis lung cancer test shows higher sensitivity in clinical trial
-
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
-
Personalis to Participate in Upcoming Investor Conferences
-
Personalis Reports Second Quarter 2025 Financial Results
-
Personalis to Announce Second Quarter 2025 Financial Results
-
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Personalis extends Tempus partnership to include colorectal cancer testing
-
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
-
Personalis, Inc. (PSNL) announces presentation of results from CALLA phase 3 study at ASCO 2025
-
Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
-
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
-
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
-
Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
-
Personalis Reports First Quarter 2025 Financial Results
-
Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
-
Personalis to Announce First Quarter 2025 Financial Results
-
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
-
Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
